Emcure Pharmaceuticals shares in spotlight on receiving CDSCO approval to market Poviztra for fatty liver treatment

This followed the Central Drugs Standard Control Organisation's (CDSCO) approval of 'Wegovy' for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to a regulatory filing dated July 20.

Poviztra is manufactured and imported from Novo Nordisk's European manufacturing facility and contains innovator rDNA-origin semaglutide, it added.

Last year, in November, Novo Nordisk India and Emcure Pharma had announced a partnership to launch weight loss medicine Poviztra, semaglutide injection 2.4 mg, as a second brand of Wegovy in India.

The approval enables Emcure and its subsidiaries to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options, the company said.

Commenting on the development, Emcure Pharmaceuticals Ltd CEO & MD Satish Mehta said, “The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease.”

Last week, Novo Nordisk India announced the receipt of approval from the CDSCO for the indication of its Wegovy injection in the treatment of fatty liver disease in India.

It made Wegovy the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity, it added.

MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage.

Commenting on the development, Satish Mehta, Chief Executive Officer & Managing Director, Emcure Pharmaceuticals, said: "The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease. We are pleased to make this important new indication available through Poviztra, further strengthening our commitment to bringing globally validated, innovative therapies to patients in India. We look forward to working closely with healthcare professionals to improve awareness, encourage earlier diagnosis and expand access to evidence-based treatment for people living with MASH."

Q1 result schedule

The drugmaker said that a meeting of its board of directors has been scheduled to be held on Thursday, August 06, 2026.

At the meeting, the board will consider and approve the unaudited financial results, both standalone and consolidated, for the quarter ended June 30, 2026.

Q4 earnings snapshot

Emcure Pharmaceuticals reported a 28.81% year-on-year (YoY) surge in its consolidated net profit to ₹243.4 crore in the March quarter of the 2025-26 financial year (Q4 FY26), compared to ₹188.96 crore in the year-ago period.

Its revenue from operations jumped 16.7% YoY to ₹2,469.7 crore during the quarter under review, compared to ₹2,116.24 crore in the March quarter of the 2024-25 fiscal year (Q4 FY25).

Emcure Pharma stock performance

Shares of Emcure Pharmaceuticals surged 4.37% to close at ₹1,861.20 per unit on the National Stock Exchange (NSE) on Monday, July 20. However, the announcement was made after the market closed.

The scrip has gained 4% in the past week and 5% over the month. On a year-to-date basis, it has risen 33%.

While the stock hit a 52-week high of ₹1,944 per equity share on June 25, 2026, it touched a year’s low of ₹1,260 apiece on October 1, 2025.

Emcure Pharmaceuticals has a total market capitalisation of ₹35,318.44 crore as of July 20, 2026, according to data on the NSE.